Table 3.
Laboratory values at baseline in patients who were randomized and received study drug in PROTECT
| Characteristic | All Patients (N = 404) |
|---|---|
| UP/C, g/g | 1.2 (0.8–1.8) |
| Urinary protein excretion, g/d | 1.8 (1.3–2.8) |
| Nephrotic-range proteinuria (>3.5 g/d) | 49 (12.1) |
| UA/C, g/g | 1.1 (0.7–1.5) |
| Urinary albumin excretion, mg/d | 1493 (1073–2280) |
| eGFRa | |
| Mean ± SD | 57.0 ± 24.0 |
| Median (IQR) | 50.0 (39.0–70.0) |
| eGFR | |
| ≥90 | 51 (12.6) |
| ≥60 to <90 | 97 (24.0) |
| ≥45 to <60 | 94 (23.3) |
| ≥30 to <45 | 142 (35.1) |
| ≥15 to <30 | 20 (5.0) |
| Hemoglobin, g/l | 138.7 ± 15.9 |
| Plasma lipid profile, mmol/l | |
| Total cholesterol | 5.0 ± 1.1 |
| HDL cholesterol | 1.3 ± 0.4 |
| LDL cholesterol | 2.8 ± 1.0 |
| Triglycerides | 1.9 ± 1.1 |
| Serum albumin, g/l | |
| Mean ± SD | 41.5 ± 3.8 |
| Median (IQR) | 42.0 (40.0–44.0) |
| Serum potassium, mmol/l | 4.6 ± 0.4 |
| Serum creatinine, μmol/l | 136.1 ± 45.3 |
| Serum cystatin C, mg/l | 1.5 ± 0.4 |
| Hematuria/microscopic hematuriab | 225 (55.7) |
| ALT, U/l | 21.8 ± 10.8 |
| AST, U/l | 21.1 ± 8.0 |
ALT, alanine transaminase; AST, aspartate transferase; eGFR, estimated glomerular filtration rate in ml/min per 1.73 m2; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; UA/C, urine albumin-to-creatinine ratio; UP/C, urine protein-to-creatinine ratio.
Data are given as n (%), median (IQR), or mean ± SD. A central laboratory was used for all laboratory testing analyses.
eGFR was determined using the Chronic Kidney Disease Epidemiology formula.
The assessment of microscopic hematuria was limited by the use of a central laboratory, resulting in an unreliable analysis because of the transport time and analysis delays.